UnknownUnicorn2993086

UnknownUnicorn2993086

Depending on where the market is headed, by all means, follow the money. Here are the Top 10 Holdings $ABT $MDT $TMO $DHR $BDX $ISRG $BSX $SYK $BAX $EW

UnknownUnicorn2993086 Updated 

Stretch valuation Higher expenses weighing in on operating margin Lower demand due to change in preference ( all-natural is said to be the trend )

UnknownUnicorn2993086 Updated 

Tariff negotiation gives way to an upside until Q4. Just do it. It's December anyway. PT new 52wk highs.

UnknownUnicorn2993086 Updated 

Below $281 is just right but should be a lot lower IMO. Sell until just before earnings then reevaluate

UnknownUnicorn2993086 Updated 

Q4 Pullback was expected, not a big deal; Stock price elevated because of news and same old pump and dump. Epidiolex didn't ship until November 1st. 3 Positive Phase 3 from Sativex - FDA meeting for regulatory pathway to U.S. expected in December. Resumed @ Piper Jaffray on Nov 5th as overweight; The Street updated to sell after the drop; Market edge on avoid. ...

UnknownUnicorn2993086 Updated 

-- Second-quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018 -- Second-quarter fiscal 2019 GAAP net income was $50.1 million or $1.09 per diluted share, up 104% compared to GAAP net income of $24.5 million or $0.54 per diluted share for the prior-year period

UnknownUnicorn2993086 Updated 

At this point, I feel sorry for whoever's shorting this. Recorded $97 million on revenues this past Q2; +68% 200SMA, +24% 50SMA, +12% 20SMA, and backed by Medicare. Having worked in a hospital for so long and witnessed so many patients who will probably be in O2 the rest of their life, I can't believe that I ignored this company a few months ago. Who wants to...

UnknownUnicorn2993086 Updated 

$TNDM was once a $300 stock, struggled on sales and debt. At the time, they did not have the supreme product and it crashed. Compare to $PODD Omnipod that only has bolus and you have to manually suspend, you would want to be with t-slim if you are a diabetic patient. T-slim x2 is marketed globally, sales are up on Q2. Expecting a BIG Q3 from these guys. Pullback?...

UnknownUnicorn2993086

Net income increased by 191.5% when compared to the same quarter one year prior, rising from $6.37 million to $18.57 million. Net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Technology industry. The Street - Buy Credit Suisse - Outperform Market Edge - Long Zacks - Strong Buy Short Float - 1.18%

UnknownUnicorn2993086

I don't feel the need to tell you why you should put some money here. You're welcome. You're all welcome.

UnknownUnicorn2993086

Avoid. or Lose

UnknownUnicorn2993086

The past quarters were a bust. Today it came out with $1.18 per share; beating estimates of $1.15 per share. Compare to $1.01 a year ago. Long from here, stop loss @ 78.50

UnknownUnicorn2993086

Inogen is increasing its full year 2018 total revenue guidance range to $345 to $355 million, up from $340 to $350 million, representing growth of 38.3% to 42.3% versus 2017 full year results. The Company still expects direct-to-consumer sales to be its fastest growing channel, domestic business-to-business sales to have a significant growth rate, and...

UnknownUnicorn2993086

8 Sec Filings today, here's one: investor.tandemdiabetes.com They're buying, I like this stock let's see. Yes, it's a bear market i know.

UnknownUnicorn2993086

Alright one more shot. Need O2 here, so much pullback.

UnknownUnicorn2993086

Rinse and repeat. It never fails.

UnknownUnicorn2993086

you know it.

UnknownUnicorn2993086

Sep-26-18 Reiterated Piper Jaffray Overweight $32 to $56 Sep-26-18 Reiterated Dougherty & Company Buy $45 to $56 -31.25% off 52 wk high, pullback to somewhere around $31 while the market sell-off. We should be good to go for another run. BUY. Your decision if you want to hold through earnings this October. Let me know